


CLAIMS:

1. A compound of general formula (I),



5

any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof,

wherein

Q is $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2\text{CH}_2-$;

one of R^1 and R^2 is $-\text{CH}_2\text{CH}_2\text{CH}_2\text{R}^3$, $-\text{CH}_2\text{CH=CH-R}^3$, or $-\text{CH}_2\text{C}\equiv\text{C-R}^3$;

wherein R^3 is aryl or heteroaryl;

which aryl and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of:

halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, alkoxy,

cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl; and the other of R^1 and R^2 is $-\text{CO-R}^4$;

wherein R^4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl.

10

2. The compound according to claim 1, wherein

Q is $-\text{CH}_2\text{CH}_2-$.

15

3. The compound according to claim 1, wherein

Q is $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

4. The compound according to any one of claims 1-3, wherein

one of R^1 and R^2 is $-\text{CH}_2\text{CH=CH-R}^3$;

wherein R^3 is defined as in claim 1.

20

5. The compound according to any one of claims 1-4, wherein R^4 is alkyl.

6. The compound according to claim 1, wherein

Q is $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2\text{CH}_2-$;

one of R^1 and R^2 is $-\text{CH}_2\text{CH=CH-R}^3$, or $-\text{CH}_2\text{C}\equiv\text{C-R}^3$;

wherein R^3 is phenyl; and

the other of R¹ and R² is -CO-R⁴;
wherein R⁴ is alkyl.

7. A compound of claim 1 which is

(±)-1-[9-(3-Phenyl-allyl)-3,9-diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one;
(±)-1-[10-(3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one;
(±)-1-[3-(3-Phenyl-allyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one;
or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1-7, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
9. The use of a compound according to any one of claims 1-7, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the opioid receptor.
10. The use according to claim 9, wherein the disease, disorder or condition responsive to modulation of the opioid receptor is pain, postoperative pain, chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, drug addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, or head trauma.
11. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-7, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.